HBM Alpha Therapeutics Raises Seed Funding – FinSMEs

HBM Alpha Therapeutics, a Cambridge, MA-based biotechnology company incubated byHarbour BioMed (HKEX: 02142), raised a Seed funding round of undisclosed amount.

The company intends to use the funds to advance its leading programs, novel antibody therapies to treat congenital adrenal hyperplasia and polycystic ovary syndrome, with the lead candidate currently in IND-enabling stage.

HBM Alpha Therapeutics is a company presently developing antibody therapeutics aimed at the rare genetic disease congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Its therapeutics could also be indicated for other endocrinological diseases related to the dysregulation and function of the hypothalamus-pituitary-adrenal (HPA) axis.

HBMAT was founded on the expertise of Harbour BioMeds antibody discovery and development capabilities, and expertise in the molecular pathogenesis and treatment of endocrine disorders of HBMATs Scientific Founder Dr.Joseph Majzoub, Professor of Pediatrics and Medicine at Boston Childrens Hospital. HBMAT has licensed relevant technologies from Boston Childrens Hospital. Dr. Majzoub chairs the Scientific Advisory Board for HBMAT and is a shareholder of the company. At present, HBMATs Scientific Advisory Board comprises Dr. Majzoub, Dr.Frank Grosveld, Co-founder and CSO of Harbour Antibodies and the inventor of Harbour Mice, and Dr. IeuanHughes, a paediatric endocrinologist and an emeritus professor of paediatrics at theUniversity of Cambridge.

FinSMEs

26/01/2023

More:
HBM Alpha Therapeutics Raises Seed Funding - FinSMEs